Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Mar 27 | 2023Could Breyanzi Receive a CHMP Positive Opinion This Week? Abecma Starts EMA Assessment in ≥3L MM; March’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, TCR, Topics Mar 23 | 2023Strategic Combination of TCR2 Tx and Adaptimmune; Upcoming Clinical Updates for Gavo-cel and TC-510; TCR2 Tx Q4 2022 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Mar 22 | 2023Francesco Marincola Departs Kite as Head of Cell Therapy Research; Yescarta Significantly Improved OS in 2L LBCLAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Mar 17 | 2023Abecma’s sBLA Filing in ≥3L MM Remains on Track for Q1 2023; No Pipeline Updates; 2seventy bio Q4 2022 Earnings Summary; Gracell Acquires Patent Licenses from SeagenAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, Dual/triple agonist Mar 14 | 2023GC012F’s Ph1/2 Trials in the US and China to Initiate in 2023; Will FasTCAR-Ts be as Fast as Initially Thought? Gracell’s Q4 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19, CD22, CS1 Mar 10 | 2023Cellectis’s UCART20x22 Trial in NHL Starts Enrollment; Precision’s Azer-cel and PBCAR19B Programs Delayed; Poseida to Provide Further Clinical Updates in 2023; Cellectis, Precision, and Poseida Q4 2022 Earnings Calls SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Mar 09 | 2023Obe-cel’s BLA Submission on Track for YE 2023; Full FELIX Trial Data to be Presented at ASCO 2023; LCM Initiatives for Obe-cel Detailed; Partnering Opportunity for AUTO8 in MM; Autolus Q4 2022 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, TCR Mar 07 | 2023Strategic Merger of Adaptimmune and TCR2 Tx; Afami-cel's BLA Filing Completion on Track for Mid-2023; Progress in ADP-A2M4CD8’s Clinical Development; Adaptimmune Q4 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Mar 02 | 2023ALLO-501A’s Pivotal Trial in ≥3L DLBCL Top Priority for 2023; Clinical Development of BCMA CAR-Ts Postponed Until 2024; Allogene’s Q4 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Feb 24 | 2023Breyanzi Absent from February’s CHMP HighlightsAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19, TCR Feb 24 | 2023Clinical Results from P-MUC1C-ALLO1 and P-BCMA-ALLO1; Novel Allogeneic CAR-T (P-ckit-ALLO1) for AML; Upcoming Milestones for Poseida; Poseida’s R&D Day SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 20 | 2023Christi Shaw to Depart Gilead and Kite LeadershipAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 20 | 2023Type II Variation for Breyanzi Listed in February’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 14 | 2023Topline Results from Abecma's KarMMa-3 in ≥3L MM; BMS, Gilead (Kite), and Novartis Present Clinical Updates from Leading CAR-T Assets; EBMT - EHA CAR-T Meeting 2023 Analysis 2Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Feb 13 | 2023Cellpoint (Galapagos) and Takeda Present Novel CAR-Ts for Hematological Tumors; EBMT - EHA CAR-T Meeting 2023 Analysis 1Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 03 | 2023Gilead Reports Strong Cell Therapy Revenues; ZUMA-23 Delayed? New Galapagos Asset Added to the Pipeline; Gilead’s Q4 2022 Earnings Call Summary; Gracell Reports FDA IND Clearance for GC012F in R/R MMAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 03 | 2023Increased Sales for Abecma and Breyanzi; BMS to Ramp Up Manufacturing Capacity in 2023; No Clinical or Regulatory Updates; BMS Q4 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 02 | 2023Kymriah’s Sales Remain Flat; YTB323 to Be Evaluated in 1L HR LBCL; No Updates for PHE885; Novartis Q4 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Feb 01 | 2023Thoughts on Carvykti’s CARTITUDE-4 Meeting Its Primary Endpoint in 2 - 4L MMAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jan 27 | 2023Breyanzi Meets Primary Endpoint in Pivotal Trial for R/R CLLAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.